Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.

Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK.

Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.

PMID:
16782211
2.

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

Belanoff JK, Blasey CM, Clark RD, Roe RL.

Diabetes Obes Metab. 2010 Jun;12(6):545-7. doi: 10.1111/j.1463-1326.2009.01185.x.

PMID:
20518810
3.

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK.

Adv Ther. 2009 Oct;26(10):959-69. doi: 10.1007/s12325-009-0070-1. Epub 2009 Nov 4.

PMID:
19888560
4.

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.

Gross C, Blasey CM, Roe RL, Belanoff JK.

Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51. Epub 2010 Mar 25.

5.

Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.

Belanoff JK, Blasey CM, Clark RD, Roe RL.

Eur J Pharmacol. 2011 Mar 25;655(1-3):117-20. doi: 10.1016/j.ejphar.2011.01.019. Epub 2011 Jan 24.

PMID:
21269600
6.

LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.

Sindelar DK, Carson MW, Morin M, Shaw J, Barr RJ, Need A, Alexander-Chacko J, Coghlan M, Gehlert DR.

J Pharmacol Exp Ther. 2014 Jan;348(1):192-201. doi: 10.1124/jpet.113.205864. Epub 2013 Oct 25.

7.

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.

Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB.

Schizophr Res. 2008 Aug;103(1-3):94-103. doi: 10.1016/j.schres.2008.05.011. Epub 2008 Jun 25.

PMID:
18579346
8.

Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.

Deng C, Lian J, Pai N, Huang XF.

J Psychopharmacol. 2012 Sep;26(9):1271-9. doi: 10.1177/0269881112449396. Epub 2012 Jun 13.

PMID:
22695490
9.

Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.

Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD.

Neuropsychopharmacology. 2007 Feb;32(2):284-8. Epub 2006 May 10.

10.

Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Davoodi N, Kalinichev M, Korneev SA, Clifton PG.

Psychopharmacology (Berl). 2009 May;203(4):693-702. doi: 10.1007/s00213-008-1415-1. Epub 2008 Dec 4.

PMID:
19052729
11.

Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.

Han M, Deng C, Burne TH, Newell KA, Huang XF.

Psychoneuroendocrinology. 2008 Jun;33(5):569-80. doi: 10.1016/j.psyneuen.2008.01.018. Epub 2008 Mar 20.

PMID:
18358632
12.

Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats.

Fell MJ, Neill JC, Anjum N, Peltola LM, Marshall KM.

J Psychopharmacol. 2008 Mar;22(2):182-6. doi: 10.1177/0269881107082287. Epub 2008 Feb 28.

PMID:
18308803
13.

Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.

Patil BM, Kulkarni NM, Unger BS.

Eur J Pharmacol. 2006 Dec 3;551(1-3):112-5. Epub 2006 Sep 16.

PMID:
17046744
14.

The role of thermogenesis in antipsychotic drug-induced weight gain.

Stefanidis A, Verty AN, Allen AM, Owens NC, Cowley MA, Oldfield BJ.

Obesity (Silver Spring). 2009 Jan;17(1):16-24. doi: 10.1038/oby.2008.468. Epub 2008 Oct 30.

15.

Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.

Shobo M, Yamada H, Mihara T, Kondo Y, Irie M, Harada K, Ni K, Matsuoka N, Kayama Y.

Behav Brain Res. 2011 Jan 20;216(2):561-8. doi: 10.1016/j.bbr.2010.08.046. Epub 2010 Sep 15.

PMID:
20816897
16.

Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.

Fell MJ, Marshall KM, Williams J, Neill JC.

J Psychopharmacol. 2004 Jun;18(2):149-55.

PMID:
15260902
17.

Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.

Davey KJ, Cotter PD, O'Sullivan O, Crispie F, Dinan TG, Cryan JF, O'Mahony SM.

Transl Psychiatry. 2013 Oct 1;3:e309. doi: 10.1038/tp.2013.83.

18.

A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.

Sejima E, Yamauchi A, Nishioku T, Koga M, Nakagama K, Dohgu S, Futagami K, Kataoka Y.

Cell Mol Neurobiol. 2011 Oct;31(7):985-9. doi: 10.1007/s10571-011-9663-8. Epub 2011 Jun 17.

PMID:
21681559
19.

Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.

Minet-Ringuet J, Even PC, Goubern M, Tomé D, de Beaurepaire R.

Appetite. 2006 May;46(3):254-62. Epub 2006 Mar 23.

PMID:
16551485
20.

Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.

Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN.

Psychopharmacology (Berl). 2005 Oct;182(2):220-31. Epub 2005 Oct 19.

PMID:
16001110

Supplemental Content

Support Center